Investment Rating - The report maintains a "Recommended" investment rating for Poly Property (6049.HK) [1][3][12] Core Views - Poly Property's 2024 revenue is projected to be 16.34 billion yuan, representing a year-on-year growth of 8.5%, while the net profit attributable to shareholders is expected to reach 1.47 billion yuan, an increase of 6.8% [4][6] - The company plans to increase its dividend payout ratio to 50%, up by 10 percentage points from the previous year, reflecting a commitment to returning value to shareholders [6][7] Summary by Sections Financial Performance - In 2024, the company expects to achieve a revenue of 16.34 billion yuan, with a year-on-year growth rate of 8.5% [5] - The net profit for 2024 is forecasted at 1.47 billion yuan, which is a 6.8% increase compared to the previous year [5] - The gross margin is projected to be 18.3%, while the net margin is expected to be 9.1% [5][10] Business Operations - The total managed area for 2024 is estimated at 800 million square meters, with a contract area of 990 million square meters, indicating a strengthening of scale advantages [6] - The proportion of third-party projects and non-residential types in the managed area is 65.4% and 60.9%, respectively, showing an optimized business mix [6] Growth Strategy - The company is focusing on enhancing community value-added services and has launched the "Oriental Courtesy" brand for high-end services [6] - In 2024, the revenue from third-party property management services is expected to account for 42.7% of total revenue, an increase of 1.6 percentage points year-on-year [6] Financial Projections - The projected earnings per share (EPS) for 2024 is 2.66 yuan, with estimates for 2025 and 2026 at 2.84 yuan and 3.00 yuan, respectively [5][10] - The price-to-earnings (P/E) ratio is expected to be 10.8 for 2024, decreasing to 9.2 by 2027 [10]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company is focusing on the development of dual antibodies and ADC platforms, enhancing its product matrix in oncology and autoimmune diseases. Key products include CMG901 and CM313, with ongoing clinical trials expected to yield significant data in the near future [2][3] - The company is expected to see revenue growth driven by the commercialization of its core product, Siponimod, and the anticipated partnerships for CM313 and CM355, leading to an upward revision of earnings forecasts for 2025-2026 [4][10] Summary by Sections Product Development - The company is advancing multiple dual antibodies and ADC drugs, including CM512, CM336, CM355, CM350, CM380, and CM518D1, which are aimed at solidifying its competitive position in the oncology and autoimmune sectors [3] - CMG901 is undergoing several global clinical studies for various cancers, with data expected to validate its competitive edge [2] Financial Forecast and Valuation - The company is projected to achieve revenues of 699 million in 2025, 1.113 billion in 2026, and 1.869 billion in 2027, reflecting growth rates of 63% and 59% respectively [11] - The net profit is expected to improve significantly, with a forecasted profit of 46 million by 2027, indicating a turnaround from previous losses [11] Market Position - The company is well-positioned in the autoimmune sector with a strong pipeline and the potential for international expansion of its ADC and dual antibody platforms [4][10]

Investment Rating - The report maintains a "Buy" rating for the company [9]. Core Insights - The company is characterized as a long-term investment target with both "good sector" and "good company" attributes, being a rare all-business leader. Its excellent commercial operation capabilities enable steady growth in shopping center operations, while quality property management capabilities drive scale and revenue growth. The company has demonstrated financial strength by maintaining a 100% dividend payout for two consecutive years, indicating robust cash reserves and a flexible decision-making mechanism that is expected to support long-term development [2][10]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 17.04 billion (up 15.4%) and a net profit attributable to shareholders of 3.63 billion (up 23.9%). The core net profit attributable to shareholders was 3.51 billion (up 20.1%), with a comprehensive gross margin of 32.9% (up 1.1 percentage points). The annual dividend payout ratio was 100%, resulting in a dividend yield of 4.7% [6][10]. Shopping Center Operations - The company experienced resilient growth in commercial operations, further solidifying its industry leadership. In 2024, retail sales increased by 18.7% to 215 billion (with a comparable growth rate of 4.6%), outperforming the overall retail sales growth of 3.5%. Rental income from owners reached 26.2 billion (up 19.2%), and net operating income (NOI) grew by 20.0% to 17.1 billion. The company opened 21 new shopping centers in 2024, marking the highest number in its history, and ended the year with a total of 122 shopping centers [10]. Property Management - The company’s property management segment saw an increase in managed area to 413 million square meters (up 11.6%). The revenue from property management reached 10.71 billion (up 11.6%), driven by scale expansion. The gross margin for property management was 17.0% (down 0.5 percentage points) [10]. Future Projections - The company is expected to achieve net profits attributable to shareholders of 4.34 billion, 4.98 billion, and 5.58 billion for the years 2025, 2026, and 2027, respectively, with growth rates of 19%, 15%, and 12%. The corresponding price-to-earnings ratios are projected to be 17, 15, and 13 times [2][10].

Investment Rating - The report recommends a selection of ten stocks across various sectors, indicating a positive outlook for these companies [4]. Core Insights - The report highlights the potential for double-digit growth in earnings for companies like China Biopharmaceuticals and Sichuan Road and Bridge, driven by strong market demand and innovative product pipelines [5][6]. - The report emphasizes the importance of product differentiation and market positioning for companies such as Maogeping and Transsion Holdings, which are expected to benefit from their unique offerings and market strategies [10][11]. - The report also notes the significant land value gains and high dividend yields for Shenzhen International, suggesting a favorable investment environment [14]. Summary by Sector 1. Pharmaceuticals - China Biopharmaceuticals (1177.HK) is expected to achieve nearly 50% revenue from innovative drugs by 2025, with a strong growth trajectory anticipated [5]. 2. Construction - Sichuan Road and Bridge (600039.SH) is projected to see a turnaround in performance due to new demand from infrastructure projects in central and western China, alongside attractive dividend yields [6]. 3. Media - Kaiying Network (002517.SZ) is building a solid foundation with nostalgic products and a rich pipeline of new games set to launch in 2025, alongside investments in AI-driven products [7][9]. 4. Electronics - Transsion Holdings (688036.SH) is focusing on emerging markets, with a projected shipment of 106.9 million smartphones in 2024, aiming to enhance its market position through increased R&D investment [10]. 5. Consumer Goods - Maogeping (1318.HK) is positioned as a leading high-end domestic cosmetics brand, with a strong product expansion strategy and high offline repurchase rates [11]. 6. Transportation - Shenzhen International (0152.HK) is expected to benefit from significant land value gains and maintain a 50% dividend payout ratio, enhancing its investment appeal [14]. 7. Agriculture - Haida Group (002311.SZ) is entering a phase of cash flow release, with domestic growth and overseas expansion expected to drive performance [15]. 8. Overseas - Weishi Jiajie (0856.HK) is a leading tech service platform in the Asia-Pacific region, benefiting from the AI wave and digital transformation trends [16]. - Yum China (9987.HK) is focusing on market share growth through strategic repurchase plans and robust governance [18]. 9. North Exchange - Minshida (833394.BJ) is the first domestic manufacturer of aramid paper, with a strong market position and growth potential in high-performance applications [19][20].

Investment Rating - The report maintains a "Buy-A" rating for the company [1][8] Core Views - The company reported a revenue of 28.676 billion yuan for 2024, a year-on-year increase of 3.9%, while the net profit attributable to shareholders was 3.013 billion yuan, a decrease of 5.5% [1][3] - The board proposed a final dividend of 20.73 cents per share, with a payout ratio of 50% for the year [1] - The overall retail sales remained stable, with online channels showing low double-digit growth while offline channels experienced a slight decline [3][4] Revenue and Profit Analysis - In 2024, revenue from footwear, apparel, accessories, and equipment was 14.3 billion, 12.05 billion, 2.325 billion, and a year-on-year growth of 6.8%, -2.9%, and 29.3% respectively [4] - The retail sales for running, fitness, basketball, and sports lifestyle categories accounted for 28%, 15%, 21%, and 33% of total sales, with year-on-year growth rates of 25%, 6%, -21%, and -6% respectively [4] - The company’s gross margin improved to 49.4%, up 1.0 percentage points year-on-year, primarily due to better margins in the e-commerce channel [5][7] Channel Performance - Direct sales revenue decreased by 0.3% to 6.883 billion yuan, with the number of direct stores declining by 13.4% to 1,297 [5] - Wholesale revenue increased by 2.6% to 12.957 billion yuan, with wholesale stores growing by 1.6% to 4,820 [5] - E-commerce revenue grew by 10.3% to 8.305 billion yuan, with significant improvements in customer traffic and conversion rates [5][8] Future Outlook - The company is expected to continue optimizing its channel structure and enhancing customer experience, which will support steady business growth [8] - Projected revenues for 2025-2027 are 29.093 billion, 30.177 billion, and 31.517 billion yuan, with year-on-year growth rates of 1.5%, 3.7%, and 4.4% respectively [8][10]

聚力深耕，经营稳健 推荐（维持） 股价：11 港元 主要数据 | 行业 | 房地产 | | --- | --- | | 公司网址 | www.chinagreentown.com;www.gree | | | ntownchina.com | | 大股东/持股 | | | 实际控制人 | | | 总股本(百万股) | 2534.27 | | 流通 A 股(百万股) | 0 | | 流通 B/H 股(百万股) | 2534.27 | | 总市值（亿元） | 257.26 | | 流通 A 股市值(亿元) | 0 | | 每股净资产(元) | 14.33 | | 资产负债率(%) | 77.65 | 公 司 报 告 房地产 2025 年 03 月 31 日 绿城中国(3900.HK) 行情走势图 | 杨侃 | 投资咨询资格编号 | | --- | --- | | | S1060514080002 | | | BQV514 | | | YANGKAN034@pingan.com.cn | | 郑茜文 | 投资咨询资格编号 | | | S1060520090003 | | | ZHENGXIWEN239@pingan ...

Investment Rating - The report maintains an "Outperform" rating for the company [5][23]. Core Insights - The company is focusing on business adjustments and enhancing its core operations while providing generous dividends to shareholders [7][9]. - The company has shown stable growth in its cyclical business, achieving a revenue of 36.22 billion yuan in 2024, representing a year-on-year increase of 9.2% [8][10]. - The company plans to distribute 100% of its core net profit as dividends, with a total dividend of 1.900 yuan per share for the fiscal year 2024 [9][10]. - The company is leveraging technology applications, particularly AI, to drive growth and improve operational efficiency [13][14]. Financial Data and Forecasts - Revenue and Profit Forecasts: - Revenue is projected to grow from 33.18 billion yuan in 2023 to 36.22 billion yuan in 2024, with a compound annual growth rate (CAGR) of 9.2% [6][31]. - Net profit is expected to decrease from 1.95 billion yuan in 2023 to 1.15 billion yuan in 2024, reflecting a significant decline of 41.2% [6][31]. - The company anticipates a recovery in net profit to 1.48 billion yuan in 2025, with a year-on-year growth of 29% [6][31]. - Key Financial Ratios: - The gross margin is projected to be 13.0% in 2024, down from 14.5% in 2023 [11][31]. - The return on equity (ROE) is expected to improve from 7.0% in 2024 to 13.8% by 2027 [6][31]. Business Segment Performance - The company reported a revenue of 20.91 billion yuan from community space residential services in 2024, a year-on-year increase of 11.6% [10][17]. - Revenue from property and facility management services reached 9.97 billion yuan, growing by 20.1% compared to the previous year [18][20]. - The AIoT and BPaaS solutions segment generated 3.02 billion yuan in revenue, reflecting an 8.6% increase year-on-year [10][20]. Strategic Initiatives - The company is actively pursuing a diversified customer strategy, with revenue from non-developer clients increasing from 83.2% in 2023 to 88.2% in 2024 [13][14]. - The company has implemented an "asset-to-receivable" debt reduction model, recovering over 3 billion yuan in receivables in the second half of 2024 [13][14]. - The company is expanding its residential property scale, with a reported revenue of 19.23 billion yuan from residential property services in 2024, marking a 13.1% increase [17][20].

房地产 2025 年 03 月 31 日 绿城管理控股(9979.HK) 公 司 报 告 规模领先，竞争加剧 推荐（维持） 股价：2.88 港元 主要数据 | 行业 | 房地产 | | --- | --- | | 公司网址 | www.lcgljt.com | | 大股东/持股 | 绿城中国/71.28% | | 实际控制人 | 国务院国有资产监督管理委会 | | 总股本(百万股) | 2010 | | 流通 A 股(百万股) | 0 | | 流通 B/H 股(百万股) | 2010 | | 总市值（亿港元） | 57.9 | | 流通 A 股市值(亿元) | 0 | | 每股净资产(元) | 1.90 | | 资产负债率(%) | 41.84 | 行情走势图 相关研究报告 【平安证券】绿城管理控股（9979.HK）*半年报点评* 业绩增速放缓，保持行业领先地位*推荐20240826 【平安证券】绿城管理控股（9979.HK）*年报点评*高 成长与高股息兼具，配置性价比凸显*推荐20240322 证券分析师 | 杨侃 | 投资咨询资格编号 | | --- | --- | | | S1060514080002 ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2][9]. Core Views - The company has demonstrated rapid revenue growth, with a reported revenue of 6.27 billion HKD for 2024, reflecting a year-over-year increase of 28.6%. The net profit attributable to the parent company reached 1.068 billion HKD, up 21.37% year-over-year [8][9]. - The company is focusing on expanding its product matrix by launching new products that cater to consumer preferences, particularly in the vegetable product category, which saw a significant revenue increase of 59.1% in 2024 [8][9]. - The company is enhancing its distribution channels, with a total of 1,879 offline distributors and a strong online presence, achieving a revenue of 7.05 billion HKD from online channels, up 38.06% year-over-year [8][9]. Financial Data and Forecast - Total revenue is projected to grow from 4.887 billion HKD in 2023 to 8.093 billion HKD in 2025, with a year-over-year growth rate of 29% for both 2024 and 2025 [7][11]. - Net profit is expected to increase from 880 million HKD in 2023 to 1.3 billion HKD in 2025, with a year-over-year growth rate of 22% [7][11]. - The company’s gross margin is projected to remain stable, with a slight decrease to 46.81% in 2025, while the net profit margin is expected to be around 16.07% [7][11]. Market Performance - The company's stock has shown strong performance, with a closing price of 15.22 HKD as of March 31, 2025, and a 52-week price range of 6.91-15.22 HKD [2][9]. - The company’s revenue growth is supported by effective business strategies, including channel development and brand building, leading to a robust market presence [8][9].

Investment Rating - The investment rating for the company is "Outperform the Market" [5] Core Views - The company is expected to achieve profitability in the current year, with an improvement in its sales industry ranking [5] - The report highlights a focus on sales quality and a reduction in debt pressure within the year [3] Financial Performance and Forecast - Total revenue for 2023 is projected at 72,564.06 million, with a year-on-year decrease of 12.9%. For 2024, revenue is expected to decline further to 59,052.95 million, a drop of 18.6% [6] - Net profit for 2024 is forecasted at 1,064.81 million, a significant turnaround from a loss of 6,896.64 million in 2023, representing a year-on-year increase of 115.4% [6] - The company anticipates an EPS of 0.05 in 2024, increasing to 0.12 in 2025 [6] - The gross margin is expected to improve from 12.5% in 2023 to 14.6% in 2024 [6] Market Position and Sales - The company’s signed sales amount for 2024 is projected at 982.55 billion, reflecting a decrease of 30.4% year-on-year, ranking it 12th in the industry [7] - The company holds 397 projects in urban operations, property development, commercial leasing, and hotel operations, with an unsold area of approximately 77.96 million square meters [7] Cash Flow and Debt Management - As of the end of 2024, the company has cash and cash equivalents of 30.805 billion, a slight decrease of 0.4% year-on-year. Interest-bearing debt is projected at 122.801 billion, down 3.6% [7] - The net debt to adjusted capital ratio is expected to decrease to 67% by the end of 2024, a reduction of 6 percentage points from 2023 [7] Valuation - The report estimates a 2025 EPS of approximately 0.12, suggesting a valuation range of 1.24 to 1.48 per share, translating to 1.34 to 1.61 Hong Kong dollars per share [7]